Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Abelacimab (MAA868), a fully human IgG1 monoclonal antibody, targets and binds with high affinity to FXI's catalytic structural domain. This interaction ensures FXI remains in its zymogen form, effectively inhibiting activation by FXIIa or thrombin. Such a mechanism underscores Abelacimab's potential application in thromboembolic disease research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Abelacimab (MAA868), a fully human IgG1 monoclonal antibody, targets and binds with high affinity to FXI's catalytic structural domain. This interaction ensures FXI remains in its zymogen form, effectively inhibiting activation by FXIIa or thrombin. Such a mechanism underscores Abelacimab's potential application in thromboembolic disease research [1] [2]. |
Molecular Weight | N/A |
CAS No. | 2098724-83-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Abelacimab 2098724-83-3 inhibitor inhibit